InMed Pharmaceuticals(US:INM) Newsfileยท2024-10-28 11:30Core Viewpoint - InMed Pharmaceuticals has filed an additional international patent application for its proprietary small molecule drug candidate INM-901, aimed at treating neurodegenerative diseases, including Alzheimer's disease, which addresses significant unmet medical needs [3][4]. Group 1: Patent Application Details - The new PCT patent application includes methods for treating neuronal disorders associated with neurodegeneration and aims to inhibit or slow disease progression by reducing cytotoxicity in affected neurons [4]. - It specifies methods for neuroprotection, stimulating neurogenesis, enhancing activity, and improving cognitive functions, while also addressing inflammation and neuronal function markers [5]. Group 2: Drug Development and Mechanism - INM-901 targets multiple biological pathways related to Alzheimer's disease, demonstrating reduced neuroinflammation and improved neuronal function, indicating potential restoration of damage caused by the disease [7]. - The drug acts as a preferential signaling agonist of CB1/CB2 receptors, showing neuroprotective effects and impacting peroxisome proliferator-activated receptors (PPARs), which are relevant for neurodegenerative disorders [7][8]. - INM-901 can be administered orally, achieving therapeutic levels in the brain comparable to intraperitoneal injection, which may offer advantages over current approved products [8]. Group 3: Company Overview - InMed Pharmaceuticals focuses on developing proprietary small molecule drug candidates targeting CB1/CB2 receptors, with a pipeline that includes programs for Alzheimer's, ocular, and dermatological indications [9].